课题基金 / 基金详情

Development of drug by use of protease cascade of prostasin

Development of drug by use of protease cascade of prostasin
利用前列腺素的蛋白酶级联开发药物
批准号:
18390252
负责人:
TOMITA Kimio
金额:
$11.51万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

TOMITA Kimio的其他基金

相似基金

相关文献

中文摘要
翻译
高血压是导致血管系统损害的重要因素之一。肾脏中的钠调节是调节血压的最重要因素之一。上皮细胞钠通道是调节钠平衡的关键蛋白。我们报道了一种新的丝氨酸蛋白酶prostasin能激活培养细胞的上皮钠通道。前列腺素在体外和体内实验中被醛固酮刺激。原发性醛固酮增多症患者尿前列腺素排泄量增加,提示前列腺素可能在血压调节中起重要作用。因此,我们利用蛋白质组学的方法研究了前列腺素在血压调节中的作用。首先,我们分离了几个激活丝氨酸蛋白酶前列腺素的蛋白质。我们已经分离出三个激活前列腺素活性的克隆。目前,我们正在对这些蛋白质进行纯化和氨基酸鉴定,该项目正在进行中。我们必须继续进行进一步的实验。
英文摘要
Hypertension is one of the strong factors to damage vascular system. Sodium regulation in the kidney is one of the most important factors for the regulation of blood pressure. Epithelial sodium channel is key protein in the regulation of Na balance. We reported that a new serine protease prostasin can activate epithelial sodium channel in cultured cells. Prostasin was stimulated by aldosterone in vitro and in vivo experiments. In human, urinary prostasin excretion was elevated in primary aldosteronism, suggesting that prostasin may have significant roles in the regulation of blood pressure. Therefore, we have investigated to elucidate the roles of prostasin in the regulation of blood pressure by use of proteomics. At first, we have isolated several proteins which activate serine protease prostasin. We have already isolated three clones which activated prostasin activity. We now under experiments to purify and identify of amino acid of these proteinsThis projects is now underway. We must continue further experiments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/j.1744-9987.2007.00454.x
发表时间: 2007-02-01
期刊: THERAPEUTIC APHERESIS AND DIALYSIS
影响因子: 1.9
作者: [Naruse, Mashiro, Sakaguchi, Shunichi, Tomita, Kimio]
通讯作者: Tomita, Kimio
Successful treatment of a patient with severe calcific uremic arteriolopathy(calciphylaxis) by etidronate disodium
依替膦酸二钠成功治疗严重钙化性尿毒症性小动脉病(钙化防御)患者
DOI: --
发表时间: 2006
期刊: Am J Kidney Dis. 48(1)
影响因子: --
作者: [Shiraishi, N]
通讯作者: N
Successful treatment of a patient with severe calcific arteriolopathy(alciohylaxis)by etidronate disodium
依替膦酸二钠成功治疗严重钙化性小动脉病(抗酒精)患者
DOI: --
发表时间: 2006
期刊: Am J Kidney Dis. 48(1)
影响因子: --
作者: [Shiraishi N, ら]
通讯作者:
Target haemoglobin concentrations in chronic kidney disease
慢性肾脏病的目标血红蛋白浓度
DOI: --
发表时间: 2007
期刊: Lancet 369
影响因子: --
作者: [Nonoguchi, H., Nakayama, Y., Tomita, K. et.al.]
通讯作者: K. et.al.
8
    Mechanism of prostasin-induced aldosterone production
    • 批准号:
      20390238
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.81万
    • 财政年份:
      2008
    • 负责人:
      TOMITA Kimio
    • 依托单位:
    Antibody treatment against hypertension
    • 批准号:
      16390246
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.77万
    • 财政年份:
      2004
    • 负责人:
      TOMITA Kimio
    • 依托单位:
    Analysis of the function of prostasin in the transgenic mice.
    • 批准号:
      14370321
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.83万
    • 财政年份:
      2002
    • 负责人:
      TOMITA Kimio
    • 依托单位:
    Role of renal arginase in acute renal failure
    • 批准号:
      11470219
    • 项目类别:
      Grant-in-Aid for Scientific Research (B).
    • 资助金额:
      $9.34万
    • 财政年份:
      1999
    • 负责人:
      TOMITA Kimio
    • 依托单位:
    国内基金
    海外基金
    靶向Na⁺-糖酵解轴:²³Na-MRI无创评估宫颈癌化疗耐药与疗效预测研究
    • 批准号:
      JCZRLH202600284
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    深紫外双折射晶体Na[BF2(CN)2]大尺寸单晶生长工艺研发
    • 批准号:
      JCZRQNB202600441
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    SCNN1G通过Na+/CSNK2A1/NF-κB轴塑造膀胱癌非炎症型微环境并介导免疫治疗耐药的机制研究
    多元素(19F/23Na/31P/129Xe)磁共振成像前沿研究